Cure Pharmaceutical Holding Corp.
Orodispersible dosage form platform technology that enhances drug absorption and bioavailability by avoiding first-pass metabolism
- Sector
- Medtech
- Headquarters
- OXNARD, CA
- Founded
- 2014
- Latest Form D
- $11.5M, Nov 2020
- Total capital
- $31.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $31.5M
- 3 Form D · last Nov 2020
- 71 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 3 pending · first 2021
- Rank in peer group#10 of 73
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$11.5M
- Private capital raisedForm D · SEC · 2nd filing$19M
- Private capital raisedForm D · SEC · 1st filing$1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 73 peers
Line = medianMedtech · Platform
- Granted patents#10 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan EinsteinDirectorNamed in SEC Form D filings
- Alex KatzExecutive OfficerNamed in SEC Form D filings
- Anya GoldinDirectorNamed in SEC Form D filings
- Charles BermanDirectorNamed in SEC Form D filings
- EDWARD MALISKIExecutive OfficerNamed in SEC Form D filings
- Gene SalkindDirectorNamed in SEC Form D filings
Show all 16 people
- Jessica RoussetExecutive OfficerNamed in SEC Form D filings
- John BellDirectorNamed in SEC Form D filings
- Josh HeldDirectorNamed in SEC Form D filings
- Lauren ChungDirectorNamed in SEC Form D filings
- Mark UdellExecutive OfficerNamed in SEC Form D filings
- Mike RedardExecutive OfficerNamed in SEC Form D filings
- Nancy DuitchDirectorNamed in SEC Form D filings
- Robert DavidsonExecutive Officer, DirectorNamed in SEC Form D filings
- Ruben King-ShawDirectorNamed in SEC Form D filings
- William YuanDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 10- PendingOral Dissolvable Film And Method Of Manufacturing And Using The SameUSPTOApplication 17758215
- GrantedPharmaceutical Composition And Method Of ManufacturingUSPTOUS 11,478,520
- GrantedRapidly Disintegrating Oral Dissolvable FilmUSPTOUS 11,344,506
Show all 10 patent records
- Oral Dissolvable Film And Method Of Manufacturing And Using The SameJun 8, 2023 · Application 17758215Pending
- Pharmaceutical Composition And Method Of ManufacturingOct 25, 2022 · US 11,478,520Granted
- Rapidly Disintegrating Oral Dissolvable FilmMay 31, 2022 · US 11,344,506Granted
- Pharmaceutical Composition And Method Of ManufacturingMay 31, 2022 · US 11,344,591Granted
- Pharmaceutical Composition And Method Of ManufacturingMay 17, 2022 · US 11,331,358Granted
- Methods And Compositions For Improving SleepMay 17, 2022 · US 11,331,309Granted
- Pharmaceutical Composition And Method Of ManufacturingMar 8, 2022 · US 11,266,702Granted
- Oral Soluble Film Containing Sildenafil CitrateNov 23, 2021 · US 11,179,331Granted
- Oral Dissolvable Film And Method Of Manufacturing And Using The SameApplication PCTUS2020067677Pending
- Rapidly Disintegrating Oral Film MatrixApplication PCTUS2019041328Pending
Related companies, and why
- NeuroPsyCADSimilar federal contract value in Medtech · null in contracts
- Applied Research and PhotonicsSimilar federal contract value in Medtech · null in contracts
- IKONISYS INCSimilar federal contract value in Medtech · null in contracts
- BRIOPRYME BIOLOGICS, INC.Similar federal contract value in Medtech · null in contracts
- BIOTISSUE HOLDINGS INC.Similar federal contract value in Medtech · null in contracts
- CT RESOURCES INCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .